About US
Contact us
-
SFDA:Provisions for Drug Insert Sheets and LabelsSFDA:Provisions for Drug Insert Sheets and Labels (SFDA Decree No.24) The Provisions for Drug Insert Sheets and Labels, adopted at the executive meeting of the State Food and D2009/12/31
-
SFDA:Provisions for Import and Export of Anabolic Agents and Peptide Hormones (Interim)SFDA:Provisions for Import and Export of Anabolic Agents and Peptide Hormones (Interim) (SFDA Decree No. 25)The Provisions for Import and Export of Anabolic Agents and Peptide2009/12/31
-
SFDA issues Good Manufacturing Practice for Medical Devices (interim) and Requirements for Medical Device GMP Inspection (interim)In order to intensify supervision on medical device manufacturing, standardize quality management systems for medical device manufacturing, strengthen the management of medical device GMP insp2009/12/31
-
PTC Therapeutics Closes $50-Million FinancingPTC Therapeutics, Inc. recently announced the completion of a $50-million financing. The round was led by The Column Group (a new investor) and existing investor Delphi Ventures. The co-lead i2009/12/30
-
Activaero’s AKITA JET Receives FDA 510(k) ClearanceActivaero, a world leader in the design of controlled breathing drug delivery technologies that maximize the efficiency and precision of inhaled drugs, recently announced that the US FDA has i2009/12/30
-
Athersys Inks Deal With Pfizer on Stem-Cell TherapyAthersys, Inc. recently announced it has entered into an agreement with Pfizer Inc. to develop and commercialize MultiStem for the treatment of Inflammatory BowlDisease (IBD). MultiStem is an2009/12/30
-
InSite Vision to Advance New Ocular Anti-Inflammatory CandidateInSite Vision Incorporated, a company developing ophthalmic products for unmet eye care needs, recently announced plans to advance new development candidate ISV-303, a topical anti-inflammator2009/12/29
-
Isis Pharmaceuticals to Receive $10 Million From OncoGenex’s License of OGX-011 to TevaIsis Pharmaceuticals, Inc. recently announced that it will receive a $10-million payment from OncoGenex Pharmaceuticals, Inc. as a result of OncoGenex's license of OGX-011 to Teva Pharmaceutic2009/12/29
-
Makefield Therapeutics Licenses Patent Rights Covering Its Hybrid Nanoparticle Delivery PlatformMakefield Therapeutics, Inc., an emerging therapeutics company, recently announced it has obtained an exclusive license from Albert Einstein College of Medicine of Yeshiva University to patent applica2009/12/29
-
IPEC-AMERICAS NEWSSOURCE: WEB OF IPECIPEC American news20091228(2).rar2009/12/28